Abstract

Nifedpine in Compounded Oral and Topical Preparations

Author(s): McCluskey Susan V, Brunn Gregory J

Issue: Mar/Apr 2011 - Volume 15, Number 2

Page(s): 166-169

Download in electronic PDF format for $75
  • Nifedpine in Compounded Oral and Topical Preparations Page 1
  • Nifedpine in Compounded Oral and Topical Preparations Page 2
  • Nifedpine in Compounded Oral and Topical Preparations Page 3
  • Nifedpine in Compounded Oral and Topical Preparations Page 4

Abstract

The purpose of this study was to evaluate nifedipine oral and topical compounding formulas and procedures. Topical preparations were compounded in Plastibase 50 W, using combinations of two drug sources and four types of light exposure. Oral preparations were compounded using combinations of two drug sources, two types of light exposure, and four suspending vehicles. Drug sources consisted of the contents of commercial nifedipine soft-gelatin capsules and nifedipine powder USP. Light exposures were ambient, red-shaded, goldshaded fluorescent light, or a combination of ambient and gold-shaded fluorescent light. Topical formulations were assessed for potency, uniformity, and usability characteristics such as acceptable look and feel of the preparation. Oral formulations were assessed for potency, uniformity, and usability characteristics, such as acceptable look and taste of the preparation. Preparations which were compounded, in entirety, under gold-shaded fluorescent light with nifedipine powder USP as the drug source resulted in a potency of 90% to 110% of intended value. Preparations that were exposed to ambient or red-shaded fluorescent light at any time in the compounding procedure resulted in subpotent preparations. Nifedipine is sensitive to certain wavelengths of light resulting in rapid degradation. When exposed to fluorescent room light, significant degradation may occur in a time frame less than what may be required to compound a preparation, necessitating the need for compounding to take place under a spectrum of light that will not degrade the drug. Gold fluorescent lighting appears to prevent nifedipine degradation during compounding procedures. Concerning the drug source, the use of commercial nifedipine soft gelatin capsules was problematic, while nifedipine powder USP is a suitable choice for the active pharmaceutical ingredient.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2011
Pg. 166-169
Jul/Aug 2004
Pg. 269-274
May/Jun 2020
Pg. 200-205
Author(s): Allen Loyd V Jr
Sep/Oct 2015
Pg. 357-365
Jul/Aug 2021
Pg. 344-351
Sep/Oct 2011
Pg. 435-437
Jan/Feb 2004
Pg. 10-14
Author(s): Preckshot John
Jul/Aug 2013
Pg. 307-311
Author(s): McElhiney Linda F
Sep/Oct 2018
Pg. 387-398
Nov/Dec 2020
Pg. 501-508
Jan/Feb 2002
Pg. 34-37
Author(s): Allen Loyd V Jr
Mar/Apr 2019
Pg. 167-175
Mar/Apr 2016
Pg. 155-158
May/Jun 2022
Pg. 219-228
Author(s): Allen Loyd V Jr
Jul/Aug 2022
Pg. 270-274
Author(s): Riepl Mike
Mar/Apr 2016
Pg. 159-163
Sep/Oct 2011
Pg. 422
Author(s): Allen Loyd V Jr
Sep/Oct 2011
Pg. 423
Author(s): Allen Loyd V Jr
Jul/Aug 2006
Pg. 303
Author(s): Allen Loyd V Jr
Mar/Apr 2021
Pg. 131-139
Author(s): Allen Loyd V Jr